Funding for this research was provided by:
National Institutes of Health (R01HL089336)
Article History
First Online: 16 October 2020
Declarations
:
: Preparation of this manuscript was supported in part by Grant number R01HL089336 from the National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, MD, USA, Robert M. Carney, Principal Investigator, The Taylor Family Institute for Innovative Psychiatric Treatments, and the Center for Brain Research in Mood Disorders at Washington University.
: Lauren Behlke has no conflicts of interest that are directly relevant to the content of this article. Eric Lenze has received research grants from Takeda, Janssen, Lundbeck, Acadia, PCORI, Barnes Jewish Hospital, McKnight Brain Research Foundation, and Aptinyx, and consulting fees from Janssen and Jazz Pharmaceuticals. Robert M. Carney or a member of his family owns stock in Pfizer, Incorporated.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the review and to the writing of the manuscript.